Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Breast Neoplasm Female Clinical Trial

Official title:

BOOG 2017-03: Endocrine Therapy Plus CDK 4/6 Inhibition in First- or Second-line for Hormone Receptor Positive Advanced Breast Cancer - the SONIA Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03425838
• Other study ID #: BOOG 2017-03
• Secondary ID: 2017-002334-23
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: November 9, 2017
• Est. completion date: December 2025

Study information

• Verified date: August 2023
• Source: Borstkanker Onderzoek Groep
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather than second line endocrine treatment, the aim of this project is to evaluate whether the sequence of an aromatase inhibitor plus CDK 4/6 in first line followed by fulvestrant in second line is superior to the sequence of an aromatase inhibitor in first line followed by fulvestrant plus CDK4/6 in second line.

Description:

Combining cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors with endocrine therapies in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer has shown to result in substantial improvements in progression-free survival. There is however no evidence that this combination strategy leads to an improved overall survival. Furthermore, no specific subgroups that will or will not benefit from the combination of drugs have been identified yet. This means the optimal strategy for deploying CDK 4/6 inhibitors in clinical practice is not yet known. Since CDK 4/6 inhibitors are costly and can have toxic effects, it is important to determine the optimal treatment strategy to avoid both over- and undertreatment. The SONIA-trial is an investigator-initiated, multicenter, randomized phase III study. The primary objective of this study is to evaluate if treatment with a non-steroidal aromatase inhibitor combined with CDK 4/6 inhibition in first line followed at progression by fulvestrant in second line (strategy A) improves progression-free survival compared to treatment with a non-steroidal aromatase inhibitor in first line followed at progression by fulvestrant combined with CDK4/6 inhibition in second line (strategy B). The primary end point is progression-free survival after two lines (PFS2), secondary end points include overall survival, quality of life, safety and biomarker analyses.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1050
• Est. completion date: December 2025
• Est. primary completion date: March 6, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult women (= 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of loco-regional recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent and for whom chemotherapy is not clinically indicated.

2. Documentation of histologically or cytologically confirmed diagnosis of estrogen-receptor (ER) expression >10% and/or progesterone receptor (PR) expression >10% breast cancer based on local laboratory results.

3. Previously untreated with any systemic anti-cancer therapy for loco-regional recurrent or metastatic HR+ disease, with the exception of recently started (within 28 days of randomization) endocrine therapy.

4. Women who are not post-menopausal must use LHRH agonist. Postmenopausal status is

defined as:

1. prior bilateral surgical oophorectomy, or

2. spontaneous cessation of regular menses for at least 12 consecutive months without OAC

3. in case of doubt serum estradiol <20 umol/l and follicle stimulating hormone (FSH) levels >15 IU/L at screening

5. Measurable or evaluable disease as defined per RECIST v.1.1 (see Appendix 3) or bone-only disease. Tumor lesions previously irradiated or subjected to other locoregional therapy will only be deemed measurable if disease progression at the treated site after completion of therapy is clearly documented.

6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.

7. Adequate organ and marrow function defined as follows:

1. ANC =1,000/mm3 (1.0 x 10e9 /L);

2. Platelets =50,000/mm3 (50 x 10e9 /L);

3. Estimated creatinine clearance = 30 mL/min as calculated using the method standard for the institution;

4. Total serum bilirubin =1.5 x ULN (=3.0 x ULN if Gilbert's disease);

5. AST and ALT =3 x ULN (=5.0 x ULN if liver metastases present);

8. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 4.0 Grade =1, except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion.

9. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

10. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legal representative) has been informed of all pertinent aspects of the study before any study-specific activity is performed.

Exclusion Criteria:

1. Patients with advanced, symptomatic, visceral spread, who are at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions (pleural, pericardial, peritoneal), pulmonary lymphangitis, and over 50% liver involvement).

2. Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases or cord compression are eligible if they have been definitively treated with local therapy (e.g., radiotherapy, stereotactic surgery) and are clinically stable without the use of steroids for at least 4 weeks before randomization

3. Prior neoadjuvant or adjuvant treatment with an aromatase inhibitor (i.e., anastrozole, letrozole or exemestane) with disease recurrence while on or within 12 months of treatment.

4. Prior treatment with any CDK4/6 inhibitor.

5. Patients treated within the last 7 days prior to randomization with:

1. Food or drugs that are known to be CYP3A4 inhibitors (ie, amprenavir, atazanavir, boceprevir, clarithromycin, conivaptan, delavirdine, diltiazem, erythromycin, fosamprenavir, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, verapamil, voriconazole, and grapefruit or grapefruit juice);

2. Drugs that are known to be CYP3A4 inducers (ie, carbamazepine, felbamate, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentin, and St. John's wort).

6. Major surgery, chemotherapy, radiotherapy, any investigational agents, or other anti-cancer therapy within 2 weeks before randomization. Patients who received prior radiotherapy to =25% of bone marrow are not eligible independent of when it was received.

7. Diagnosis of any other malignancy prior to randomization, except those that are not believed to influence the patient's prognosis and do not require any further treatment. This includes, but is not limited to adequately treated basal cell or squamous cell skin cancer and carcinoma in situ of the cervix.

8. QTc >480 msec at baseline

9. Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection.

10. Known hypersensitivity to letrozole or anastrozole, or any of its excipients, or to any palbociclib excipients.

11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

12. Recent or active suicidal ideation or behavior.

Related Conditions & MeSH terms

• Breast Neoplasm Female
• Breast Neoplasms

Intervention

Drug:
• CDK 4/6 inhibitor
Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
• Non-Steroidal Aromatase Inhibitor
Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
• Fulvestrant
Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer

Locations

Country	Name	City	State
Netherlands	Noordwestziekenhuisgroep	Alkmaar
Netherlands	ZGT	Almelo
Netherlands	Flevoziekenhuis	Almere
Netherlands	Meander Medisch Centrum	Amersfoort
Netherlands	Ziekenhuis Amstelland	Amstelveen
Netherlands	AMC	Amsterdam
Netherlands	BovenIJ Ziekenhuis	Amsterdam
Netherlands	Nki - Avl	Amsterdam
Netherlands	OLVG	Amsterdam
Netherlands	VUmc	Amsterdam
Netherlands	Gelre ziekenhuizen	Apeldoorn
Netherlands	Rijnstate	Arnhem
Netherlands	Wilhelmina ziekenhuis	Assen
Netherlands	Rode Kruis Ziekenhuis	Beverwijk
Netherlands	Alexander Monro Ziekenhuis	Bilthoven
Netherlands	Maasziekenhuis Pantein	Boxmeer
Netherlands	Amphia	Breda
Netherlands	IJsselland	Capelle Aan Den IJssel
Netherlands	Reinier de Graaf	Delft
Netherlands	Jeroen Bosch Ziekenhuis	Den Bosch
Netherlands	Haaglanden Medisch Centrum	Den Haag
Netherlands	HaGaziekenhuis	Den Haag
Netherlands	Deventer Ziekenhuis	Deventer
Netherlands	Van Weel-Bethesda Ziekenhuis	Dirksland
Netherlands	Slingeland Ziekenhuis	Doetinchem
Netherlands	Albert Schweitzer ziekenhuis	Dordrecht
Netherlands	Nij Smellinghe	Drachten
Netherlands	Gelderse Vallei	Ede
Netherlands	Catharina Ziekenhuis	Eindhoven
Netherlands	Maxima Medisch Centrum	Eindhoven
Netherlands	Treant Zorggroep	Emmen
Netherlands	Medisch Spectrum Twente	Enschede
Netherlands	St. Anna Ziekenhuis	Geldrop
Netherlands	Admiraal de Ruyter	Goes
Netherlands	Rivas Beatrixziekenhuis	Gorinchem
Netherlands	Groene Hart Ziekenhuis	Gouda
Netherlands	Martini Ziekenhuis	Groningen
Netherlands	UMC Groningen	Groningen
Netherlands	Ropcke Zweers	Hardenberg
Netherlands	Sint Jansdal	Harderwijk
Netherlands	Tjongerschans	Heerenveen
Netherlands	Elkerliek ziekenhuis	Helmond
Netherlands	Tergooi	Hilversum
Netherlands	Spaarne Gasthuis	Hoofddorp
Netherlands	Dijklander Ziekenhuis	Hoorn
Netherlands	MC Leeuwarden	Leeuwarden
Netherlands	Alrijne Ziekenhuis	Leiden
Netherlands	LUMC	Leiden
Netherlands	St. Antonius	Nieuwegein
Netherlands	Canisius-Wilhelmina Ziekenhuis	Nijmegen
Netherlands	Radboudumc	Nijmegen
Netherlands	Laurentius	Roermond
Netherlands	Bravis ziekenhuis	Roosendaal
Netherlands	Erasmus MC	Rotterdam
Netherlands	Franciscus Gasthuis & Vlietland	Rotterdam
Netherlands	Ikazia	Rotterdam
Netherlands	Maasstad Ziekenhuis	Rotterdam
Netherlands	Zuyderland	Sittard
Netherlands	Antonius Ziekenhuis	Sneek
Netherlands	Spijkenisse Medisch Centrum	Spijkenisse
Netherlands	ZorgSaam	Terneuzen
Netherlands	Ziekenhuis Rivierenland	Tiel
Netherlands	Elisabeth Tweesteden	Tilburg
Netherlands	Bernhoven	Uden
Netherlands	Diakonessenhuis	Utrecht
Netherlands	UMC Utrecht	Utrecht
Netherlands	VieCuri	Venlo
Netherlands	St. Jans Gasthuis	Weert
Netherlands	Streekziekenhuis Koningin Beatrix	Winterswijk
Netherlands	Zaans Medisch Centrum	Zaandam
Netherlands	Langeland	Zoetermeer
Netherlands	Isala	Zwolle

Sponsors (1)

Lead Sponsor	Collaborator
Borstkanker Onderzoek Groep

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS2	Progression-free survival after two lines of treatment (PFS2)	Until objective disease progression, symptomatic deterioration, or unacceptable toxicity on second line treatment, death, strategy violation, or withdrawal of consent, whichever occurs first, assessed up to 60 months
Secondary	OS	Overall survival	Date of randomization until date of death due to any cause, assessed up to 60 months
Secondary	FACT-B questionnaire	Quality of Life questionnaire	Questionnaires will be administered at baseline and thereafter every three months, up to 60 months
Secondary	EQ-5D questionnaire	Quality of Life questionnaire	Questionnaires will be administered at baseline and thereafter every three months, up to 60 months
Secondary	iMTA RUQ-B questionnaire	Quality of Life questionnaire	Questionnaires will be administered at baseline and thereafter every six months, up to 60 months
Secondary	Number of participants with grade 3 or 4 treatment-related neutropenia as assessed by CTCAE v4.0	Safety assessment will consist of monitoring of all grade 3 and grade 4 neutropenia (absolute neutrophil count/L)	Through study completion, assessed up to 60 months
Secondary	Number of participants with grade 3 or 4 treatment-related thrombocytopenia as assessed by CTCAE v4.0	Safety assessment will consist of monitoring of all grade 3 and grade 4 thrombocytopenia (platelet count/L)	Through study completion, assessed up to 60 months
Secondary	Number of participants with grade 3 or 4 treatment-related anemia as assessed by CTCAE v4.0	Safety assessment will consist of monitoring of all grade 3 and grade 4 anemia (mmol/L)	Through study completion, assessed up to 60 months
Secondary	Number of participants with grade 3 or 4 treatment-related elevated liver enzymes (ALAT/ASAT/AF/GGT/bilirubin) as assessed by CTCAE v4.0	Safety assessment will consist of monitoring of all grade 3 and grade 4 elevated liver enzymes (elevation compared to upper limit of normal)	Through study completion, assessed up to 60 months
Secondary	Number of participants with grade 3 or 4 treatment-related other toxicities as defined in CTCAE v4.0	Safety assessment will consist of monitoring of all grade 3 and grade 4 other toxicities as defined in CTCAE v4.0	Through study completion, assessed up to 60 months
Secondary	Cost-effectiveness by means of a decision model (a multistate Markov model or a Discrete Event Simulation model)	The cost and outcomes of both arms will be assessed by means of a decision model (a multistate Markov model or a Discrete Event Simulation model). Cost-effectiveness will be determined by comparing costs and effects of both treatment strategies. Quality adjusted life years will be computed by multiplying life-years with the observed utility scores during those life years. The friction cost method will be used for estimating the societal costs of productivity losses. Unit costs for drugs will be derived from www.medicijnkosten.nl or the Z-index. The costs of a hospital day, outpatient visit, and day care treatment, will be based on the Dutch costing manual. Other costs will be collected from NZA tariffs. All costs will be expressed in Euros.	At 60 months after entry into the study
Secondary	ORR	Objective response rate	Through study completion, assessed up to 60 months
Secondary	Plasma through levels	Plasma through levels of CDK4/6 inhibitor measured in blood samples obtained at cycle 1, day 15 (of 28 days in one cycle) and at cycle 2, day 15 in participants treated with CDK4/6 inhibitors.	Through study completement
Secondary	Pharmacogenomics	DNA sequencing in a blood sample obtained at cycle 1, day 15 (of 28 days in one cycle) of treatment with CDK4/6 inhibitor.	On day 15 of cycle 1 (a cycle is 28 days)
Secondary	Liquid biopsies	Circulating tumor DNA isolated from blood samples collected at 7 timepoints during the study. Mutation level during the study and at disease progression will be compared to base-line mutation level.	At baseline of first line, at cycle 1 day 15 (a cycle is 28 days), at cycle 4 day 1, at baseline of second line, at cycle 1 day 15 (a cycle is 28 days), at cycle 4 day 1 and at disease progression
Secondary	Tissue microarray	Tissue microarray on archived FFPE tissue blocks of the tumor	At baseline